Morgan Stanley Analysts Give Fresenius SE & Co KGaA (FRE) a €50.00 Price Target

Morgan Stanley set a €50.00 ($58.14) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note released on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Tuesday, February 12th. Berenberg Bank set a €70.95 ($82.50) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Monday, February 18th. Nord/LB set a €58.00 ($67.44) price objective on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Wednesday, February 20th. Warburg Research set a €65.00 ($75.58) price objective on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Wednesday, February 20th. Finally, Kepler Capital Markets set a €58.00 ($67.44) price objective on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Thursday, February 21st. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Fresenius SE & Co KGaA currently has an average rating of Buy and a consensus target price of €59.55 ($69.24).

FRA:FRE opened at €48.01 ($55.83) on Thursday. Fresenius SE & Co KGaA has a fifty-two week low of €60.16 ($69.95) and a fifty-two week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: Blockchain

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.